| Tumour Group / Site |
Trial Title |
Opening Date |
Breast
Adjuvant |
Phase 3 trial of Metforim vs placeo in adjuvant breast cancer to evaluate the effects of Metformin on breast ca outcomes, including recurrence & deat, (MA.32) |
August
2009 |
|
A phase II study of foretinib in patients with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negative, recurrent/metastatic breast cancer (NCIC CTG IND.197) |
November 2010 |
|
Phase I/II study of Foretinib in combination with Lapatinib in pts with human epidermal growth factor receptor 2 (HER2) over-expressing metastatic breast ca. (NCIC IND.198) ON HOLD |
January 2011 |
|
A phase II study of RO4929097 in advanced, metastatic, or recurrent triple negative invasive breast carcinoma (NCI 8561/PHL 076) |
September 2011 |
|
A Randomized, Double-blind, placebo-controlled, multi-centre phase 3 study of Denosumab as adjuvant treatment for women with early-stage breast cancer at high risk of recurrence (D-CARE Amgen) |
January 2012 |
|
A phase II prospective trial correlating progression-free survival with CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen (E3108) |
February
2012 |
|
Top |
| Central Nervous System (CNS) |
|
|
| Top |
| GI - Colorectal |
Open-label, multicentre, randomized phase 2 study evaluating the safety & efficacy of 5-FU/FA + oxaliplatin (modified FOLFOX-6) in combination with IMC-1121B or IMC-18F1 or without investigational therapy as second-line therapy in pts with metastatic colorectal cancer following disease progression on first-line Irinotecan-based therapy. (CP20-0801) |
January 2011 |
|
Phase 3 trial of Irinotecan / 5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab or cetuximab (C225), or with combo of bevacizumab & cetuximab for pts with untreated metastatic ca of colon or rectum (NCIC CRC.5) |
July 2011
|
|
A phase III Trial of 6 versus 12 treatments of Adjuvant Folfox plus Celecoxib or placebo for patients with resected stage III Colon Cancer (CRC.6) |
January 2012 |
|
Colorectal cancer tissue banking study. |
January 2012 |
|
Top |
| GU - Bladder |
|
|
| GU - Prostate |
A Randomized Phase 3 Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by a High Dose of 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by a 125Iodine Brachytherapy Implant Boost for Patients with Intermediate and High Risk Localized prostate Cancer (ASCENDE-RT) |
August 2004 |
|
RADICALS:Radiotherapy and Androgen Deprivation In Combination After Local Surgery - A randomized controlled controlled trial in prostate cancer. (NCIC PR.13) |
June 2009 |
|
Prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate adenocarcinoma post external beam RT.(RTOG 0526) |
Jan 2010 |
|
A Phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma (RTOG 0232) |
Mar. 2010 |
|
A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients with Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease.OGX-427 (PR-01) |
March 2011 |
|
A multinational phase 3, randomized, double blinded, placebo controlled efficacy and safety study of oral MDV3100 in chemotherapy-naïve patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy (PREVAIL) |
April 2011 |
|
Open-Label study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostrate Cancer who have progressed after taxane-based chemotherapy (AA EAP) |
May 2011 |
|
High Dose Rate Prostate (HDR) Brachytherapy with vitesse - a Varian research collaboration proposal evaluating Vitesse one-step US-based HDR Prostate Brachytherapy (Vitesse (Varian) |
May 2011 |
|
|
A randomized double blinded, placebo-controlled phase III trial to evaluate the effectiveness of a phosphodiesterase 5 inhibitor, Tadalafil, in prevention of Erectile Dysfunction (ED) in patients treated with radiotherapy for Prostate Cancer. (RTOG 0831) |
Dec 2011 |
|
A phase II study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer. (NCIC IND.205) |
Dec 2011 |
|
A Phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer (RTOG 0815) |
Jan 2012 |
| GU - Renal |
|
|
|
|
|
| GU - Multi |
An open-label, multicenter, randomized Phase 2 study evaluating the safety and efficacy of docetaxel in combination with ramucirumab(IMC-1121B) or IMC-18F1 orwithout investigational therapy as a second line therapy in patients with locally advanced or metastatic transitional cell carcinoma of the bladder, urethra, ureter or renal pelvis following disease progression on first line platinum-based therapy. (CP20-0902) |
Dec 2011 |
| Top |
|
Gyne |
A randomized trial of concurrent Cediranib (AZD2171) (with platinum-based chemotherapy) & maintenance Cediranib in women with platinum-sensitive relapsed ovarian cancer (NCIC OV.18) |
July 2008 |
|
Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (Farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer (MORAb-003-003) |
November 2010 |
|
A Phase II/III Study of Intrapertioneal (IP) plus Intravenous (IV) Chemotherapy vs. IV Carboplatin + Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy (NCIC OV-21) |
March 2011 |
|
Top |
| Top |
Lung
|
|
|
|
Top |
|
Lymphoma
|
Phase 2 trial investigating tailoring first-line therapy for advanced stage diffuse large B-Cell NHL based on mid treatment positron emission tomography (PET) Scan Result (PET Scan in DLBCL) (LYTPET) |
November 2006
|
|
Phase 3 study of Bendamustine compared with Bendamustine + RO5072759 (GA101) in pts with Rituximab-Refractory, Indolent Non-Hodgkin’s Lymphoma GA04753g (GA101) |
March 2011 |
Multiple Myeloma
|
|
|
|
Top |
| Melanoma |
|
|
| Top |
| Supportive |
A Randomized double-blind, double-summy, 2-treatment, 2-period, cross-over comparison of sennosides and polyethylene glycol for constipation in outpatients with cancer (Sennosides PEG) |
August 2010 |